Rebeccamycin

• UNSPSC Description:

  Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II[1][2].

• Target Antigen:

  ADC Cytotoxin; Antibiotic; Topoisomerase

• Type:

  Natural Products

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Anti-infection;Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/rebeccamycin.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1)C(C2=C3N([C@@H]([C@@H]([C@@H](O)[C@@H]4OC)O)O[C@@H]4CO)C5=C2C=CC=C5Cl)=C(C(C6=CC=C7)=C3NC6=C7Cl)C1=O

• Molecular Weight:

  570.38

• References & Citations:

  [1]Merchant J, et al. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res. 2002 Jul;8(7):2193-201.|[2]Bush JA, et al. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot (Tokyo). 1987 May;40(5):668-78.|[3]Sánchez C, et al. The biosynthetic gene cluster for the antitumor rebeccamycin: characterization and generation of indolocarbazole derivatives. Chem Biol. 2002 Apr;9(4):519-31.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  93908-02-2